Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | EYA2 | O00167 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 5/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6228115 | 0.79 | FFAR3 (0.48) | MVDPHF8KDM2ANPC1RAB9A | |
| SCHEMBL2804753 | 0.79 | EPHX2 (0.46) | MVDPHF8KDM2ATDP1KDM4A | |
| SCHEMBL10256732 | 0.78 | MVD (0.44) | MVDACEPHF8KDM2AEYA2 | |
| SCHEMBL29434566 | 0.77 | SLC22A6 (0.50) | MVDPHF8KDM2AKDM4AKDM4C | |
| SCHEMBL28427604 | 0.77 | PHF8 (0.41) | MVDACEPHF8KDM2ANPC1 | |
| SCHEMBL11737268 | 0.77 | MVD (0.41) | MVDACEPHF8KDM2ANPC1 | |
| SCHEMBL4589551 | 0.77 | TSHR (0.43) | KDM5AKMT2A | |
| SCHEMBL18666669 | 0.76 | ACE (0.42) | ACEPHF8KDM2AFOLH1EYA2 | |
| SCHEMBL31305127 | 0.76 | FFAR3 (0.44) | MVDPHF8KDM2ANPC1RAB9A | |
| SCHEMBL6936379 | 0.76 | ALDH1A1 (0.58) | APPTDP1KDM4CKDM5AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080166362-A1 | New effector conjugates, process for their production and their pharmaceutical use | BERGER MARKUS | 2008-07-10 | — | — | US | disclosed |
| US-7335775-B2 | Effector conjugates, process for their production and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-02-26 | — | — | US | disclosed |
| US-20070088060-A1 | New effector conjugates, process for their production and their pharmaceutical use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-04-19 | — | — | US | disclosed |
| US-7129254-B2 | Effector conjugates, process for their production and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-31 | — | — | US | disclosed |
| EP-1524979-A2 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | Schering AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| US-20050026971-A1 | New effector conjugates, process for their production and their pharmaceutical use | SCHERING AG (DE) | 2005-02-03 | — | — | US | disclosed |
| WO-2004012735-A2 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | SCHERING AG (DE) | 2004-02-12 | — | — | WO | disclosed |
| US-4775662-A | ASTHMA TREATMENT, ANTIALLERGENS, BRONCHODILATOR AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1988-10-04 | — | — | US | disclosed |
| EP-0121350-B1 | SUBSTITUTED UNSATURATED MERCAPTOCARBOXYLIC ACIDS AND DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1987-05-13 | — | — | EP | disclosed |
| EP-0121350-A2 | Substituted unsaturated mercaptocarboxylic acids and derivatives as leukotriene antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1984-10-10 | — | — | EP | disclosed |
| US-4339600-A | ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1982-07-13 | — | — | US | disclosed |
| US-4199512-A | Compounds for alleviating hypertension | E. R. SQUIBB & SONS, INC. (US) | 1980-04-22 | — | — | US | disclosed |
| US-4173704-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1979-11-06 | — | — | US | disclosed |
| US-4140786-A | ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4140797-A | MERCAPTOACYL AMINO ACIDS, ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4112119-A | MERCAPTOACYL AMINOACIDS | E. R. SQUIBB & SONS, INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4053651-A | MERCAPTOACYL AMINO ACIDS, ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166362-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | MVD 15/4885ACE 3422/4885PHF8 3130/4885 |
| US-20050026971-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | MVD 15/4885ACE 3422/4885PHF8 3130/4885 |
| US-20070088060-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | MVD 15/4885ACE 3422/4885PHF8 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.